Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults - AZD2816

Study identifier:D7220C00001

ClinicalTrials.gov identifier:NCT04973449

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase II/III Partially Double-Blinded, Randomised, Multinational, Active-Controlled Study in Adults to Determine the Safety and Immunogenicity of AZD2816, a Vaccine for the Prevention of COVID-19

Medical condition

COVID-19

Phase

Phase 2/3

Healthy volunteers

Yes

Study drug

-

Sex

All

Actual enrollment

2848

Study type

Interventional

Age

18 Years - 115 Years

Date

Study Start Date: 27 Jun 2021
Primary Completion Date: 04 Feb 2022
Study Completion Date: 02 Aug 2022

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Prevention

Verification:

Verified 01 Jan 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria